Treatment of psychosis, aggression, and irritability in patients with epilepsy

Epilepsy and Behavior

Volumn 3, Issue 5 SUPPL. 1, 2002, Pages 13-18

  Alper, Kenneth R ^a   Barry, John J ^b   Balabanov, Antoaneta J ^c  

^a NEW YORK UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

Antidepressants drugs; Antiepileptic drugs; Antipsychotic drugs; Depression; Intractable epilepsy; Psychosis of epilepsy

Indexed keywords

AMFEBUTAMONE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ASCENDIN; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; LOXAPINE; LOXAPINE SUCCINATE; LYSERGIDE; MAPROTILINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TOPIRAMATE; UNINDEXED DRUG; VIGABATRIN; ZIPRASIDONE; ZONISAMIDE;

AGGRESSION; AKATHISIA; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; BRAIN INJURY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG USE; DYSTONIA; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; IRRITABILITY; LONG QT SYNDROME; MOOD DISORDER; NEUROPSYCHIATRY; NEUROTOXICITY; PATHOGENESIS; PATIENT SELECTION; PSYCHOSIS; REVIEW; SEIZURE; SEIZURE THRESHOLD; SOMNOLENCE; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

EID: 0036816913     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1525-5069(02)00500-5     Document Type: Review

References (51)

1. Morel B. D'une forme de delire, suite d'une surexcitation nerveuse se rattachant a une variete non encore decrite d'epilepsie. Gaz Hebd Med Chir 1850;7:773-5.
2. Farlet JP. Del'etat des epileptiques. Arch Gen Med 1861;17:461-91.
3. Hill D. Psychiatric disorders of epilepsy. Med Press 1953;229:473-5.
4. Pond DA. Psychiatric aspects of epilepsy. J Indian Med Prof 1957;3:141-5.
5. Slater E, Beard AW, Glithero E. The schizophrenia-like psychosis of epilepsy. V. Discussion and conclusions. Br J Psychiatry 1963;109:95-150.
6. Torta R, Keller R. Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999;40:S2-S20.
7. Kanner AM. Psychosis of epilepsy: a neurologist's perspective. Epilepsy Behav 2000;1:219-27.
8. Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav 2000;1:100-5.
9. Blumer D. Dysphoric disorders and paroxysmal affects: recognition and treatment of epilepsy-related psychiatric disorders. Harv Rev Psychiatry 2000;8:8-17.
10. Kanner AM, Barry JJ. Is the psychopathology of epilepsy different from that of nonepileptic patients? Epilepsy Behav 2001;2:170-86.
11. Marsh L, Krauss GL. Aggression and violence in patients with epilepsy. Epilepsy Behav 2000;1:160-8.
12. Mendez MF, Doss RC, Taylor JL. Interictal violence in epilepsy. Relationship to behavior and seizure variables. J Nerv Ment Dis 1993;181:566-9.
13. Barry JJ, Huynh N. Psychotropic drug use in patients with epilepsy and developmental disabilities. In: Devinsky O, Westbrook LE, editors. Epilepsy and developmental disabilities. Burlingon: Butterworth-Heinemann; 2002. p. 45-71.
14. Sachdev P. Schizoprenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998;155:325-36.
15. Kanemoto K, Tsuji T, Kawasaki J. Reexamination of interictal psychoses based on DSM IV psychosis classification and international epilepsy classification. Epilepsia 2001;42:98-103.
16. Ketter TA, Malow BA, Flamini R, White SR, Post RM, Theodore WH. Anticonvulsant withdrawal-emergent psychopathology. Neurology 1994;44:55-61.
17. Tucker C. Safety assessment for the postictal confusional phase following complex partial seizure. J Neurosurg Nurs 1985;17(3):201-9.
18. Duffy A, Grof P, Robertson C, Alda M. The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 2000;61:630-7.
19. Alper K, Devinsky O, Westbrook L, et al. Premorbid psychiatric risk factors for postictal psychosis. J Neuropsychiatry Clin Neurosci 2001;13:492-9.
20. Ojemann LM, Baugh-Bookman C, Dudley DL. Effect of psychotropic medications on seizure control in patients with epilepsy. Neurology 1987;37:1525-7.
21. Gross A, Devinsky O, Westbrook LE, Wharton AH, Alper K. Psychotropic medication use in patients with epilepsy: effect on seizure frequency. J Neuropsychiatry Clin Neurosci 2000;12:458-64.
22. Harmant J, van Rijckevorsel-Harmant K, de Barsy T, Hendrickx B. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet 1990;336:386.
23. Hovorka J, Herman E, Nemcova I. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy Behav 2000;1:444-7.
24. Stahl SM. "Hit-and-run" actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. J Clin Psychiatry 2001;62:670-1.
25. Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez De Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO study). BMC Psychiatry 2001;1:7.
26. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.
27. Owen Jr RR, Cole JO. Molindone hydrochloride: a review of laboratory and clinical findings. J Clin Psychopharmacol 1989;9:268-76.
28. Fish DN. Treatment of delirium in the critically ill patient. Clin Pharm 1991;10:456-66.
29. Menza MA, Murray GB, Holmes VF, Rafuls WA. Decreased extrapyramidal symptoms with intravenous haloperiodol. J Clin Psychiatry 1987;48:278-80.
30. Trimble MR. On the use of tranquilizers in epilepsy. Epilepsia 2002;43(Suppl 2):25-7.
31. Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999;53(5 Suppl 2):S68-75.
32. Barry JJ, Lembke A, Huynh N. Affective disorders in epilepsy. In: Ettinger A, Kanner A, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Philadelphia: Lippincott/Williams & Wilkins; 2001. p. 205-17.
33. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992;53:160-2.
34. Riddle MA, Bernstein GA, Cook EH, Leonard HL, March JS, Swanson JM. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 1999;38:546-56.
35. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-51.
36. Silver JM, Yudofsky SC, Slater JA, et al. Propranolol treatment of chronically hospitalized aggressive patients. J Neuropsychiatry Clin Neurosci 1999;11:328-35.
37. Yudofsky SC, Silver JM, Hales RE. Treatment of agitation and aggression. In: Schatzberg AF, Nemeroff CB, editors. American psychiatric press textbook of psychopharmacology. 2nd ed. Washington: American Psychiatric Press; 1998. p. 881-900.
38. Shankle WR, Nielson KA, Cotman CW. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995;9:233-7.
39. Gross-Tsur V, Manor O, van der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?. J Pediatr 1997;130:670-4.
40. Wroblewski BA, Leary JM, Phelan AM, Whyte J, Manning K. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992;53:86-9.
41. Shukla S, Mukherjee S, Decina P. Lithium in the treatment of bipolar disorders associated with epilepsy: an open study. J Clin Psychopharmacol 1988;8:201-4.
42. Chaudhry RP, Waters BG. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983;44:30-1.
43. Poindexter AR. Phenobarbital, propranolol, and aggression. J Neuropsychiatry Clin Neurosci 2000;12:413.
44. Khan A, Faught E, Gilliam F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. Seizure 1999;8:235-7.
45. Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000;9:65-70.
46. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001;42:1611-3.
47. Besag FM. Behavioral effects of the new anticonvulsants. Drug Saf 2001;24:513-36.
48. Brambilla P, Barale F, Soares JC. Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2001;4:421-46.
49. Beran RG, Gibson RJ. Aggressive behavior in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998;39:280-2.
50. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7.
51. Wolf SM, Shinnar S, Kang H, Gil KB, Moshe SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:1203-5.